b.well Connected Health Partners with myTomorrows to Launch AI-Driven Clinical Trial Matching Stack

Why It Matters

The integration speeds patient recruitment, cutting drug‑development timelines and costs while expanding access for diverse, community‑level populations.

Key Takeaways

• b.well’s network aggregates data from 2.4M providers and 330 insurers.
• AI engine matches verified health records to trial eligibility in real time.
• Automated pre‑screening cuts recruitment time and screening expenses.
• Permissioned consent lets patients share data securely with sponsors.
• Expanded community reach diversifies trial populations and speeds approvals.

Pulse Analysis

The biopharma industry faces a chronic bottleneck: recruiting eligible patients for clinical trials remains labor‑intensive and fragmented. Traditional approaches rely on patients manually gathering records from disparate EHRs, claims systems and wearables, creating delays that can add months to development cycles. AI‑powered matching platforms promise to streamline this process, but they require a unified, high‑quality data source to be effective.

b.well’s strength lies in its FHIR‑compliant data lake, which normalizes longitudinal health information from millions of clinicians, insurers and health exchanges. Its proprietary Data Refinery cleanses and standardizes this influx, delivering an AI‑ready record that myTomorrows’ algorithms can instantly compare against complex trial eligibility criteria. The partnership also embeds a transparent, permissioned consent layer, ensuring patients retain ownership of their data while granting sponsors real‑time access when they opt‑in. This architecture bridges the gap between raw clinical data and actionable trial opportunities.

For sponsors, the combined stack translates into measurable cost reductions and faster time‑to‑market. Automated pre‑screening lowers screen‑failure rates, trims site administrative overhead and widens geographic reach, enabling more representative cohorts. As trial diversity improves, regulatory pathways become smoother, potentially accelerating approvals. The collaboration signals a shift toward consumer‑directed health data ecosystems, positioning both b.well and myTomorrows as pivotal enablers of the next wave of precision‑medicine trials.